Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theratechnologies Inc. (T:TH)

Business Focus: Biopharmaceuticals

Oct 17, 2024 02:00 pm ET
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced data from two poster presentations, focusing...
Oct 17, 2024 07:30 am ET
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today disclosed the study design and baseline characteristics...
Oct 10, 2024 07:30 am ET
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Oct 09, 2024 07:30 am ET
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek...
Sep 26, 2024 07:30 am ET
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Sep 17, 2024 05:00 pm ET
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption...
Sep 09, 2024 07:30 am ET
Theratechnologies to Present at Upcoming Investor Conferences in September
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul...
Jul 10, 2024 07:30 am ET
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Jun 26, 2024 07:30 am ET
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
May 23, 2024 05:00 pm ET
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of...
May 09, 2024 04:30 pm ET
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of...
May 02, 2024 07:30 am ET
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy,...
Apr 15, 2024 04:15 pm ET
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024...
Apr 11, 2024 07:30 am ET
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul...
Apr 10, 2024 07:30 am ET
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Apr 08, 2024 04:30 pm ET
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the...
Apr 05, 2024 11:00 am ET
Theratechnologies Appoints Elina Tea to its Board of Directors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief...
Apr 03, 2024 07:30 am ET
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Mar 28, 2024 07:30 am ET
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the...
Mar 22, 2024 09:36 am ET
Theratechnologies Announces Update on its Preclinical Oncology Research Program
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical...
Mar 21, 2024 08:00 pm ET
Theratechnologies Appoints Jordan Zwick to its Board of Directors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief...
Mar 21, 2024 07:30 am ET
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced moving to the next dose level in Part 3 of...
Feb 29, 2024 04:34 pm ET
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from...
Feb 27, 2024 07:30 am ET
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug...
Feb 21, 2024 07:30 am ET
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Feb 20, 2024 07:30 am ET
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the publication of a peer-reviewed article...
Feb 15, 2024 07:30 am ET
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced completion of enrollment of the first six...
Feb 06, 2024 07:30 am ET
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Jan 24, 2024 07:00 am ET
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration...
Jan 23, 2024 07:30 am ET
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received correspondence from the U.S. Food and Drug...
Jan 02, 2024 07:30 am ET
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has filed a supplemental...
Dec 21, 2023 03:09 pm ET
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
MONTREAL, Dec. 21, 2023 /PRNewswire/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3.
Dec 21, 2023 03:09 pm ET
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
MONTREAL, Dec. 21, 2023 /CNW/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3.
Dec 13, 2023 07:30 am ET
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug...
Nov 24, 2023 07:30 am ET
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research...
Oct 31, 2023 12:34 pm ET
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced...
Oct 26, 2023 08:00 am ET
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has priced its previously announced...
Oct 25, 2023 04:13 pm ET
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering...
Oct 24, 2023 07:00 am ET
Theratechnologies Announces Operational Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced further changes to its operations that...
Oct 19, 2023 07:30 am ET
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today shared data demonstrating the cost-effectiveness of...
Oct 16, 2023 07:30 am ET
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has finalized all documentation...
Oct 13, 2023 07:30 am ET
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data in a poster session at ID Week 2023...
Oct 13, 2023 07:00 am ET
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced results from a study evaluating an...
Oct 12, 2023 07:30 am ET
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3...
Oct 04, 2023 07:30 am ET
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration...
Sep 26, 2023 07:30 am ET
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Sep 25, 2023 07:30 am ET
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has reached an agreement in...
Sep 25, 2023 07:00 am ET
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has filed a supplemental...
Sep 20, 2023 07:00 am ET
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and...
Sep 18, 2023 04:15 pm ET
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Sep 07, 2023 01:57 pm ET
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lévesque, President and Chief...
Sep 05, 2023 07:00 am ET
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company expects to report...
Aug 30, 2023 10:34 am ET
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U.S.-based clinical...
Aug 21, 2023 03:24 pm ET
Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /CNW/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his Company's story in an interview with TMX Group.
Jul 31, 2023 07:00 am ET
Theratechnologies Completes 1-for-4 Reverse Stock Split
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the...
Jul 28, 2023 04:44 pm ET
Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it entered into an agreement...
Jul 21, 2023 07:00 am ET
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Gary Littlejohn has resigned from...
Jul 20, 2023 07:00 am ET
Theratechnologies Announces 1-for-4 Reverse Stock Split
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that its Board of Directors...
Jul 12, 2023 07:30 am ET
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Jun 30, 2023 08:09 am ET
Canadian Investment Regulatory Organization Trading Halt - TH.DB.U
TORONTO, June 30, 2023 /CNW/ - The following issues have been halted by CIRO:
Jun 29, 2023 07:30 am ET
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and...
Jun 22, 2023 07:30 am ET
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it drew down on its second...
Jun 12, 2023 07:30 am ET
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will hold a video conference call on Tuesday, June 13,...
Jun 02, 2023 12:15 pm ET
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration...
May 25, 2023 05:31 pm ET
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1...
May 19, 2023 05:11 pm ET
Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.
/NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/
May 09, 2023 12:01 pm ET
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of...
May 04, 2023 07:30 am ET
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data from a landmark study in which the...
Apr 18, 2023 09:00 am ET
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the...
Apr 18, 2023 07:30 am ET
Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.
Apr 12, 2023 07:30 am ET
Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Apr 03, 2023 07:30 am ET
Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter...
Mar 14, 2023 06:42 pm ET
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new data will be presented...
Mar 07, 2023 06:00 am ET
Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the...
Feb 28, 2023 07:30 am ET
Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Feb 28, 2023 06:30 am ET
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has entered into a first...
Feb 22, 2023 05:30 pm ET
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may...
Feb 16, 2023 07:30 am ET
Theratechnologies Announces Path to Resume TH1902 Clinical Development
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and...
Feb 14, 2023 05:00 pm ET
Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth...
Jan 04, 2023 07:45 am ET
Open Letter to Shareholders from CEO Paul Levesque
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has...
Dec 01, 2022 06:30 pm ET
Theratechnologies Announces Update from Ongoing TH1902 Study
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the...
Oct 26, 2022 07:30 am ET
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies reports data from a tissue microarrays (TMAs) study...
Oct 13, 2022 07:30 am ET
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Oct 12, 2022 07:30 am ET
Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from...
Oct 03, 2022 03:09 pm ET
Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug...